Overview
Legal name
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Region
Unknown
Registered address
Unknown
Insolvency history
No
Company
Active
ROYAL-CHARTER
Company profile
London School of Hygiene and Tropical Medicine
The London School of Hygiene & Tropical Medicine | LSHTM
London School of Hygiene and Tropical Medicine is a UK company with status active founded in 1981.
CRN
RC000330
Founded
1981
Age
45
Corporate ownership
Updated 06 Jun 2026 16:52
London School of Hygiene and Tropical Medicine
No active corporate controller recorded.
Company events
Reference milestones and recent Companies House filing stream events.
2 events
15 Jan
2017
Confirmation statement due
Confirmation DueNext confirmation statement due date
01 Jan
1981
Incorporated
InceptionCompany registered at Companies House
Public funding
7 awards
First funded
2010
Funded years
2010, 2014, 2023, 2025
Age at first award
29 years
Projects
2025
EU-Funded
Lead participant
Optimizing the delivery and uptake of malaria vaccines in countries with areas of highly seasonal transmission in West and Central Africa
1 Jan 2025 to 30 Jun 2029
Awarded
£552,174
Total cost £552,174
The availability of effective malaria vaccines is a historic landmark, “a breakthrough for science, child health and malaria control” that “could save tens of thousands of young lives each year” [WHO 2021]. But substantial implementation challenges need to be addressed to realise this potential. In many areas where malaria vaccines will soon be introduced...
2023
EU-Funded
Lead participant
CONTAGIO
1 Dec 2023 to 30 Nov 2026
Awarded
£182,761
Total cost £182,761
CONTAGIO is a consortium of investigators from Europe, North America, Latin America, Asia, and Africa, that aims to create coordination mechanisms to rapidly react to infectious disease (re-)emergence in low- and middle-income countries (LMICs). The Consortium builds on the experience acquired through the EC-funded projects ReCoDiD, ORCHESTRA, ZIKAlliance...
2023
EU-Funded
Lead participant
Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity
1 Apr 2023 to 31 Mar 2027
Awarded
£846,884
Total cost £846,884
no public description
2023
EU-Funded
Lead participant
Efficient and rapidly SCAlable EU-wide evidence-driven Pandemic response plans through dynamic Epidemic data assimilation
1 Jan 2023 to 31 Dec 2026
Awarded
£339,999
Total cost £339,999
2014
Collaborative R&D
Research to create point-of-care TB diagnostic prototype from ProteinLogic unique TB biomarker signature and Microtest novel rapid diagnostic platform [MicroLogic].
1 Nov 2014 to 30 Apr 2015
Awarded
£31,920
Total cost £31,920
Tuberculosis (TB) is responsible for over four million deaths each year. Globally there were an estimated 8.9 million new cases during 2011 and it is also a concern in the UK where there are approximately nine thousand new cases each year. Early detection and treatment is important to prevent the disease from spreading. Current diagnostic tests either lac...
2010
Feasibility Studies
Feasibility of using recombinase polymerase amplification for a Rapid Point of Care Test for Tuberculosis
1 Aug 2010 to 31 Aug 2011
Awarded
£67,205
Total cost £84,006
Awaiting Public Summary
2010
Feasibility Studies
Ultrasensitive nanosensor arrays for detection of VOC biomarkers of tubercolosis
1 Aug 2010 to 31 Jul 2011
Awarded
£45,839
Total cost £57,299
Awaiting Public Summary
Product types
Collaborative R&D
EU-Funded
Feasibility Studies